Elinzanetant for VMS: Mechanism of Action, Onset, and Treatment Considerations

This episode, titled "Elinzanetant for VMS: Mechanism of Action, Onset, and Treatment Considerations," features panelists diving deep into the clinical rationale for selecting elinzanetant for a breast cancer survivor on adjuvant endocrine therapy, while examining the drug's unique mechanism of action and its practical implications for patient care. The experts emphasize that shared decision-making is foundational to treatment selection, noting that understanding a patient's priorities, concerns, and real-world constraints is just as important as the clinical data. They also reframe the concept of non-compliance, arguing that barriers such as cost, transportation, and lack of support systems are often the true obstacles to treatment adherence rather than patient unwillingness.

The discussion then turns to elinzanetant's mechanism of action, with one expert explaining how declining estrogen destabilizes the hypothalamic KNDy neurons responsible for thermoregulation, and how NK receptor antagonists restore balance by occupying those receptors and calming the system. The experts distinguish elinzanetant from fezolinetant by highlighting its dual NK1 and NK3 receptor antagonism — with the NK1 component targeting substance P and contributing to improvements in sleep, making it particularly well-suited for this patient.

The conversation also underscores the clinical significance of elinzanetant's rapid onset of action, with patients beginning to notice improvements within the first week. For breast cancer survivors who are struggling to remain on life-saving endocrine therapies due to debilitating VMS, this speed of relief is described as potentially practice-changing — addressing both quality and quantity of life simultaneously.

In the next episode, "Safety Monitoring and Multidisciplinary Care for VMS in Breast Cancer Survivors," panelists will discuss the safety monitoring requirements and side effect profile of elinzanetant compared to fezolinetant, and examine the critical role of multidisciplinary collaboration in delivering comprehensive, patient-centered care for breast cancer survivors managing VMS.